A team of researchers from the Sant Pau Research Institute (IR Sant Pau) has published a study in the Journal of ...

The designation will provide Lundbeck with the possibility of rolling reviews and detailed guidance to streamline the drug ...

The FDA has granted Fast Track Designation to Lundbeck’s investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).

The FDA has granted Fast Track Designation to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).

Amlenetug received Orphan Drug Designation (ODD) from the US FDA in April 2024, the EMA in May 2021 and SAKIGAKE designation ...

A downtown Auburn brewpub has announced that it is closing temporarily due to one of its owners having a terminal illness.

Alterity Therapeutics Limited (market cap: $40 million), a pharmaceutical company specializing in the development of therapeutic drugs, has secured A$40 million in funding to advance the development ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or the “Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

A new electrical stimulation therapy for spinal muscle atrophy (SMA) has shown promise in reactivating motor neurons and ...

A tribute to Simon Townsend, creator of Wonder World, celebrating his contributions to Australian children’s television and ...

MPs and campaigners say that people suffering from Motor Neurone Disease or Parkinson’s should have greater access to an ...